Kidney Cancer Journal 49
e1373237. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
29147629
24. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune
Related Adverse Effects of Immune Checkpoint Inhibitors. JAMA
Oncol Internet. 2016 Oct 1 cited 2018 Jun 13;2(10):1346. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/27367787
25. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB.
Corrigendum: Current Diagnosis and Management of Immune Related
Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
Front Pharmacol Internet. 2017 cited 2018 Jun 13;8:311. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/28579959
26. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R,
et al. Managing toxicities associated with immune checkpoint inhibitors:
consensus recommendations from the Society for Immunotherapy
of Cancer (SITC) Toxicity Management Working Group.
J Immunother Cancer Internet. 2017 Nov 21 cited 2018 Jun 13;5(1):95.
Available from: https://jitc.biomedcentral.com/articles/10.1186/s40425-
017-0300-z
27. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ,
Caterino JM, et al. Management of Immune-Related Adverse Events in
Patients Treated With Immune Checkpoint Inhibitor Therapy: American
Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol
Internet. 2018;36(17):JCO.2017.77.638. Available from: http://ascopubs.
org/doi/10.1200/JCO.2017.77.6385
28. Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et
al. Management of toxicities from immunotherapy: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J
Eur Soc Med Oncol Internet. 2017 Jul 1 cited 2018 Jun 13;28(suppl_4):
iv119-iv142. Available from: https://academic.oup.com/ annonc/article/
28/suppl_4/iv119/3958159
29. Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review
of immune-related adverse event reporting in clinical trials of immune
checkpoint inhibitors. Ann Oncol. 2015;26(9):1824–9.
30. Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et
al. Pooled analysis safety profile of nivolumab and ipilimumab combination
therapy in patients with advanced melanoma. J Clin Oncol.
2017;35(34):3815–22.
31. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B,
Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced
Renal-Cell Carcinoma. N Engl J Med Internet. 2018 Apr 5 cited
2018 Jun 13;378(14):1277–90. Available from: http://www.nejm.org/
doi/10.1056/NEJMoa1712126
32. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott
DF, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody
in Cancer. N Engl J Med Internet. 2012 Jun 28 cited 2017 Feb
19;366(26):2443–54. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/22658127
33. Mcdermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier
B, et al. Clinical activity and molecular correlates of response to atezolizumab
alone or in combination with bevacizumab versus sunitinib
in renal cell carcinoma David. Nat Med Internet. Springer US;
2018;24(June). Available from: http://dx.doi.org/10.1038/s41591-018-
0053-3
34. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab
or Monotherapy in Untreated Melanoma. N Engl J Med Internet.
2015 Sep 24 cited 2018 Jun 13;373(13):1270–1. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26398076
35. Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors.
Am J Clin Dermatol Internet. 2018 Jun 18 cited 2018 Jun
13;19(3):345–61. Available from: http://link.springer.com/10.1007/
s40257-017-0336-3
36. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel
F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone
and in combination. Nat Rev Clin Oncol Internet. Nature Publishing
Group; 2016;13(8):473–86. Available from: http://dx.doi.org/10.1038/
nrclinonc.2016.58
37. Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, et al. Antibody
mediated thyroid dysfunction during T-cell checkpoint blockade
in patients with non-small-cell lung cancer. Ann Oncol. 2017;28(3):
583–9.
38. Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A,
et al. Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis
in a Large Cohort of Patients With Metastatic Melanoma. J Clin Endocrinol
Metab Internet. 2014;99(11):4078–85. Available from:
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2014-
2306
39. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia
SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune
checkpoint inhibitor, for patients with advanced, refractory squamous
non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial.
Lancet Oncol. 2015;16(3):257–65.
40. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y,
et al. Fulminant Myocarditis with Combination Immune Checkpoint
Blockade. N Engl J Med. Internet. 2016;375(18):1749–55. Available
from: http://www.nejm.org/doi/10.1056/NEJMoa1609214
41. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased
reporting of fatal immune checkpoint inhibitor-associated myocarditis.
Lancet Internet. Elsevier Ltd; 2018;391(10124):933. Available
from: http://dx.doi.org/10.1016/S0140-6736(18)30533-6
42. Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et
al. Clinical Features, Management, and Outcomes of Immune Checkpoint
Inhibitor–Related Cardiotoxicity. Circulation Internet.
2017;136(21):2085–7. Available from: http://circ.ahajournals.org/
lookup/doi/10.1161/CIRCULATIONAHA.117.030571
43. Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint
inhibitor-related colitis in solid tumor patients: A systematic review
and meta-analysis. Oncoimmunology Internet. 2017 Oct 3 cited
2018 Jun 13;6(10):e1344805. Available from: https://www.tandfonline.
com/doi/full/10.1080/2162402X.2017.1344805 KCJ